The role of genetic variations in type I Interferons related to respiratory tract infections in Down Syndrome children.

The role of genetic variations in type I Interferons related to respiratory tract infections in Down Syndrome children. - The Down Syndrome-Interferon study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32178

Enrollment

Registered

2008-08-19

Start date

2008-08-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down Syndrome innate immunity

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Written informed consent from both parents or legal guardian (s). 2. Age 2 until and including 17 years 3. Sex: male and female 4. Ethnic background: Caucasaian and Non-Caucasian 5. Down Syndrome: Trisomy 21 due to meiotic non-dysjunction 6. Siblings: healthy, no known diseases

Exclusion criteria

Exclusion criteria: 1. Not meeting inclusion criteria 2. Clinically ill (infection) at time of venapuncture 3. Down Syndrome: Trisomy 21 due to mitotic non-dysjunction or mosaicism. 4. Siblings: with known congenital, syndromal or immunological disorders or other known diseases

Design outcomes

Primary

Measure	Time frame
The primary study parameter is to identify a difference in mRNA expression level of IFN and IFN related genes between 1: Down Syndrome children and a control group of healthy children (siblings) and 2:between different DS children.	—

Secondary

Measure	Time frame
The secondary study parameter is to identify a relationship between mRNA expression levels and current/past history of respiratory tract infections in 1. DS children compared to siblings and 2. between different DS children.	—

Countries

Netherlands

Outcome results